The need for and provision of intrathecal baclofen therapy for the management of spasticity in England: An assessment of the Hospital Episode Statistics database

BMJ Open

Volumn 5, Issue 6, 2015, Pages

  Narendran, Rajesh C ^a   Duarte, Rui V ^b   Valyi, Andrea ^c   Eldabe, Sam ^a  

^a JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c Medtronic Neuromodulation UK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; CENTRAL MUSCLE RELAXANT; DRUG IMPLANT;

ARTICLE; BRAIN DEPTH STIMULATION; DATA BASE; HUMAN; SACRAL NERVE STIMULATION; SPASTICITY; SPINAL CORD STIMULATION; CLINICAL TRIAL; DRUG IMPLANT; ENGLAND; HEALTH CARE DELIVERY; HOSPITALIZATION; INTRASPINAL DRUG ADMINISTRATION; MULTICENTER STUDY; MUSCLE SPASTICITY; NEEDS ASSESSMENT; STATISTICS AND NUMERICAL DATA; SUPPLY AND DISTRIBUTION;

BACLOFEN; DELIVERY OF HEALTH CARE; DRUG IMPLANTS; ENGLAND; HOSPITALIZATION; HUMANS; INJECTIONS, SPINAL; MUSCLE RELAXANTS, CENTRAL; MUSCLE SPASTICITY; NEEDS ASSESSMENT;

EID: 84937231368     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-007517     Document Type: Article

References (21)

1. Pandyan AD, Gregoric M, Barnes MP, et al. Spasticity: clinical perceptions, neurological realities and meaningful measurement. Disabil Rehabil 2005; 27: 2-6.
2. NHS England. Understanding the new NHS. London: BMJ, 2014.
3. NHS Commissioning Board. Clinical Commissioning Policy: intrathecal baclofen (ITB). April 2013.
4. Hospital Episode Statistics (cited 2013). http://www.hesonline.nhs.uk/
5. NHiS. http://www.nhis.info/
6. Sampson FC, Hayward A, Evans G, et al. The effectiveness of intrathecal baclofen in the management of patients with severe spasticity. Sheffield: Trent Institute for Health Services Research, Universities of Leicester, Nottingham and Sheffield, 2000. Guidance Note for Purchasers: 00/01.
7. Camberlin C, San Miguel L, Smit Y, et al. Neuromodulation for the management of chronic pain: implanted spinal cord stimulators and intrathecal analgesic delivery pumps. Health Technology Assessment (HTA). Brussels: Belgian Health Care Knowledge Centre (KCE); 2012, KCE Report 189C.
8. Penn RD, Kroin JS. Continuous intrathecal baclofen for severe spasticity. Lancet 1985; 2: 125-7.
9. Ordia JI, Fischer E, Adamski E, et al. Continuous intrathecal baclofen infusion by a programmable pump in 131 consecutive patients with severe spasticity of spinal origin. Neuromodulation 2002; 5: 16-24.
10. Vidal J, Fenollosa P, Martin E, et al. Safety and efficacy of intrathecal baclofen infusion by implantable pump for the treatment of severe spasticity: a Spanish multicentre study. Neuromodulation 2000; 3: 175-82.
11. Rawicki B. Treatment of cerebral origin spasticity with continuous intrathecal baclofen delivered via an implantable pump: long-term follow up review of 18 patients. J Neurosurg 1999; 91: 733-6.
12. Armstrong RW, Steinbok P, Cochrane DD, et al. Intrathecally administered baclofen for the treatment of children with spasticity of cerebral origin. J Neurosurg 1997; 87: 409-14.
13. Bensmail D, Ward AB, Wissel J, et al. Cost-effectiveness modeling of intrathecal baclofen therapy versus other interventions for disabling spasticity. Neurorehabil Neural Repair 2009; 23: 546-52.
14. de Lissovoy G, Matza LS, Green H, et al. Cost-effectiveness of intrathecal baclofen therapy for the treatment of severe spasticity associated with cerebral palsy. J Child Neurol 2007; 22: 49-59.
15. Albright AL, Gilmartin R, Swift D, et al. Long-term intrathecal baclofen therapy for severe spasticity of cerebral origin. J Neurosurg 2003; 98: 291-5.
16. Murphy NA, Irwin MC, Hoff C. Intrathecal baclofen therapy in children with cerebral palsy: efficacy and complications. Arch Phys Med Rehabil 2002; 83: 1721-5.
17. Albright AL, Ferson SS. Intrathecal baclofen therapy in children. Neurosurg Focus 2006; 21:e3.
18. Sampson FC, Hayward A, Evans G, et al. Functional benefits and cost/benefit analysis of continuous intrathecal baclofen infusion for the management of severe spasticity. J Neurosurg 2002; 96: 1052-7.
19. Vyawahare B, Hallas N, Brookes M, et al. Impact of the National Institute for Health and Care Excellence (NICE) guidance on medical technology uptake: analysis of the uptake of spinal cord stimulation in England 2008-2012. BMJ Open 2014; 4:e004182.
20. NHS Rightcare 2013 (updated 2013). http://www.rightcare.nhs.uk/resources
21. Health Quality Ontario. Intrathecal baclofen pump for spasticity: an evidence-based analysis. Ont Health Technol Assess Ser 2005; 5: 1-93.